



Twist Bioscience and Ginkgo Bioworks Sign New Collaboration

April 5, 2022

One of World's Largest DNA Supply Agreements Enables Diverse Product Development Across Multiple Industries

SOUTH SAN FRANCISCO, Calif. & BOSTON--(BUSINESS WIRE)--Apr. 5, 2022-- [Twist Bioscience Corporation](#) (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and [Ginkgo Bioworks](#) (NYSE: DNA), the leading horizontal platform for cell programming, today announced a new supply agreement expanding the depth and breadth of the collaboration between two of the leading organizations in the synthetic biology ecosystem. The four-year agreement includes an increased commitment by Ginkgo to purchase products from Twist, with the option to access significantly more synthesis capacity to meet Ginkgo's anticipated growth. The partnership builds on [a previous supply agreement signed](#) in 2017.

This press release features multimedia. View the full release here: <https://www.businesswire.com/news/home/20220405005337/en/>

"We love to make investments alongside incredible partners like Twist. Over the past four years, we ordered approximately one billion base pairs of synthetic DNA from Twist, allowing us to test hundreds of thousands of proteins across dozens of programs for our customers, resulting in many completed programs spanning vaccine manufacturing, food, flavor, fragrance and even cannabigerol (CBG)," said Jason Kelly, CEO of Ginkgo. "As we grow our capabilities to meet an increasing number and variety of customer needs, we are excited to continue partnering with leading companies in our ecosystem, which includes making sure we secure the high volumes of DNA that Twist is well positioned to supply."

"At Twist, we work in service of our customers, like Ginkgo, who are changing the world for the better," commented Emily M. Leproust, Ph.D., CEO and co-founder of Twist. "Together, Twist and Ginkgo facilitate new product development across multiple industries, with Twist supplying the DNA and Ginkgo programming cells. As the bioeconomy expands with new solutions to the grand challenges facing all of us, we stand ready to deliver day by day, with a vision as to how as an industry, we can truly drive positive outcomes through diverse product solutions."

About Ginkgo Bioworks

Ginkgo is building a platform to enable customers to program cells as easily as we can program computers. The company's platform is enabling biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. Ginkgo has also actively supported a number of COVID-19 response efforts, including K-12 pooled testing, vaccine manufacturing optimization and therapeutics discovery. For more information, visit www.ginkgobioworks.com.

Ginkgo Legal Notice Regarding Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding Ginkgo's anticipated growth, anticipated increased capabilities and supply agreement with Twist. These forward-looking statements generally are identified by the words "believe," "can," "project," "potential," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) the effect of Ginkgo's business combination with Soaring Eagle Acquisition Corp. ("Soaring Eagle") on Ginkgo's business relationships, performance, and business generally, (ii) risks that the business combination disrupts current plans of Ginkgo and potential difficulties in Ginkgo's employee retention, (iii) the outcome of any legal proceedings that may be instituted against Ginkgo related to its business combination with Soaring Eagle, (iv) volatility in the price of Ginkgo's securities now that it is a public company due to a variety of factors, including changes in the competitive and highly regulated industries in which Ginkgo operates and plans to operate, variations in performance across competitors, changes in laws and regulations affecting Ginkgo's business, changes in the combined capital structure and expectations associated with increases in the number of shares available for sale, (v) the ability to implement business plans, forecasts, and other expectations after the completion of the business combination, and identify and realize additional opportunities, (vi) the risk of downturns in demand for products using synthetic biology, (vii) the unpredictability of the duration of the COVID-19 pandemic and the demand for COVID-19 testing and the commercial viability of our COVID-19 testing business, and (viii) changes to the biosecurity industry, including due to advancements in technology, emerging competition and evolution in industry demands, standards and regulations. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" section of Ginkgo's annual report on Form 10-K filed with the U.S. Securities and Exchange Commission (the "SEC") on March 29, 2022 and other documents filed by Ginkgo from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Ginkgo assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Ginkgo does not give any assurance that it will achieve its expectations.

About Twist Bioscience Corporation

Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by "writing" DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products,

including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.

Follow us on [Twitter](#) | [Facebook](#) | [LinkedIn](#) | [YouTube](#)

Twist Legal Notice Regarding Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience's actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. For a description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist Bioscience's business in general, see Twist Bioscience's risk factors set forth in Twist Bioscience's Quarterly Report Form 10-Q filed with the Securities and Exchange Commission on February 9, 2022 and subsequent filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20220405005337/en/): <https://www.businesswire.com/news/home/20220405005337/en/>

For Twist Bioscience:

Angela Bitting
SVP, Corporate Affairs
Twist Bioscience
abitting@twistbioscience.com

For Ginkgo Bioworks:

press@ginkgobioworks.com

Source: Twist Bioscience Corporation